Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.
Lymphangioleiomyomatosis: What do we know and what are we looking for? / S. Harari, O. Torre, J. Moss. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 0905-9180. - 20:119(2011), pp. 34-44. [10.1183/09059180.00011010]
Lymphangioleiomyomatosis: What do we know and what are we looking for?
S. Harari;
2011
Abstract
Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.File | Dimensione | Formato | |
---|---|---|---|
034.full.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
751.99 kB
Formato
Adobe PDF
|
751.99 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.